Clinical Trials on Measles-Mumps-Rubella

Total 313 results

GlaxoSmithKline

Completed

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

Measles; Mumps; Rubella | Measles-Mumps-Rubella Vaccine

United States, Finland, Taiwan, Estonia, Puerto Rico
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Measles | Rubella | Mumps | Measles-Mumps-Rubella Vaccine

Finland, Thailand, United States, Spain, Czechia, Puerto Rico, Malaysia
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects Four to Six Years of Age

Measles-Mumps-Rubella

Taiwan, United States, Korea, Republic of
GlaxoSmithKline

Completed

Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

Measles | Rubella | Mumps | Measles-Mumps-Rubella Vaccine

United States, Puerto Rico
Shanghai Institute Of Biological Products
Victoria Biomedical Research Institute

Not yet recruiting

Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months

Measles-Mumps-Rubella
GlaxoSmithKline

Active, not recruiting

A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age

Measles; Mumps; Rubella; Chickenpox

United States, Taiwan, Spain, Argentina, Turkey, Colombia, Puerto Rico, Latvia, Chile
Rigshospitalet, Denmark

Completed

MMR at 6 Months Trial

Meales-mumps-rubella Vaccine

Denmark
Merck Sharp & Dohme LLC

Completed

ProQuad® Intramuscular vs Subcutaneous

Measles | Rubella | Mumps | Varicella
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED)

Measles | Rubella | Mumps | Varicella
Merck Sharp & Dohme LLC

Completed

Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)

Measles | Rubella | Mumps | Varicella
Merck Sharp & Dohme LLC

Completed

V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019)

Measles | Rubella | Mumps | Varicella
Merck Sharp & Dohme LLC

Completed

Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines

Measles | Rubella | Mumps | Varicella
Assistance Publique - Hôpitaux de Paris
Service de Bactériologie-Virologie-Hygiène, CHU Limoge; GO-CIC network (Réseau... and other collaborators

Completed

Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR (BREMEAVAC)

Measles | Rubella | Mumps

France
Assaf-Harofeh Medical Center

Unknown

The Influence of Probiotics on the Immunologic Response to Vaccinations in Infants

Measles | Rubella | Mumps | Immunity

Israel
GlaxoSmithKline

Completed

Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore.

Measles | Rubella | Mumps
GlaxoSmithKline

Completed

Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

Measles | Rubella | Mumps

United States, Finland, Estonia, Spain, Mexico, Puerto Rico
Takeda

Completed

Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Specified Drug-use Survey of Vaccinees After the Second Vaccination

Measles/Rubella

Japan
Takeda

Completed

Freeze-dried Live Attenuated Measles/Rubella Combined Vaccine (Schwarz FF-8 Strain/TO-336 Strain) Special Drug Use Surveillance of Vaccinees After the First Vaccination

Measles/Rubella
Centers for Disease Control and Prevention, China
Beijing Tiantan Biological Products Co., Ltd.

Completed

Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine

Measles | Rubella | Mumps | Adverse Event Following Immunisation

China
University of Zurich
Merck Sharp & Dohme LLC

Recruiting

Immunity in Persons Fully Vaccinated Against Measles, Mumps and Rubella and Responses to Booster Vaccination (MIPS)

Measles | Rubella | Mumps

Switzerland
The Immunobiological Technology Institute (Bio-Manguinhos)...

Completed

Serological Study in Children 12 to 23 Months Vaccinated With MMR (Measles, Mumps and Rubella)

Measles | Rubella | Mumps

Brazil
Sri Edupuganti, MD MPH
Merck Sharp & Dohme LLC

Completed

Measles, Mumps, and Rubella (MMR) Immunity in College Students

Measles | Rubella | Mumps

United States
GlaxoSmithKline
Parexel

Completed

Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older

Measles | Rubella | Mumps

United States, Slovakia, Estonia
The Immunobiological Technology Institute (Bio-Manguinhos)...

Completed

Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations (MMR)

Measles | Rubella | Mumps

Brazil
Merck Sharp & Dohme LLC

Completed

A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED)

Measles | Rubella | Mumps | Varicella
Merck Sharp & Dohme LLC

Terminated

A Study of ProQuad™ in Healthy Children in Korea (V221-023)

Measles | Rubella | Mumps | Varicella
Merck Sharp & Dohme LLC

Completed

ProQuad Dose Selection Study (V221-011)(COMPLETED)

Measles | Rubella | Mumps | Varicella
National Institute of Allergy and Infectious Diseases...

Terminated

Immune Responses to Two Dose Varivax +/- MMR-II

Measles | Rubella | Mumps | Varicella

United States
The Immunobiological Technology Institute (Bio-Manguinhos)...
GlaxoSmithKline

Completed

Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.

Measles | Rubella | Mumps | Varicella

Brazil
University of Michigan

Completed

Making Decisions About the Measles-Mumps-Rubella Vaccine

Measles | Rubella | Mumps | MMR Vaccination

United States
PATH

Completed

Coadministration of Measles-rubella and Rotavirus Vaccines

Measles Antibody Seroconversion | Rubella Antibody Seroconversion | Rotavirus Geometric Mean Titer (GMT) | Rotavirus Immunoglobulin A (IgA) Seropositivity

Bangladesh
Merck Sharp & Dohme LLC

Completed

ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)

Measles | Rubella | Mumps | Varicella
GlaxoSmithKline

Completed

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

Measles | Rubella | Mumps | Varicella

United States
GlaxoSmithKline

Completed

Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds

Measles | Rubella | Mumps | Varicella

Taiwan, Singapore
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children

Measles | Rubella | Mumps | Varicella

Italy
Merck Sharp & Dohme LLC

Completed

Safety Study of ProQuad® rHA in Infants (V221-037)

Measles | Rubella | Mumps | Varicella
Merck Sharp & Dohme LLC

Completed

Safety Study of a Refrigerator-stable Formulation of VARIVAX®

Measles | Rubella | Mumps | Varicella

France, Italy
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)

Measles | Rubella | Mumps | Varicella
Merck Sharp & Dohme LLC

Completed

A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)

Measles | Rubella | Mumps | Varicella
GlaxoSmithKline

Completed

Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes

Measles | Rubella | Mumps | Varicella

Germany
PT Bio Farma

Completed

Immunogenicity & Safety of Bio Farma's Measles-Rubella (MR) Vaccine in Indonesian Infants (Bridging Study)

Measles | Congenital Rubella Infection

Indonesia
Merck Sharp & Dohme LLC

Completed

Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED)

Measles | Hepatitis A | Rubella | Mumps | Chickenpox
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine

Measles | Hepatitis A | Rubella | Mumps

Turkey
National Institute of Allergy and Infectious Diseases...

Terminated

Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines

Measles | Rubella | Mumps | Varicella

United States
The Immunobiological Technology Institute (Bio-Manguinhos)...

Not yet recruiting

Immunity Duration Study Eight Years After Vaccination of Children 12 to 23 Months With the Triple Viral Vaccine (Measles, Mumps and Rubella)

Measles Vaccine
University of Rochester

Completed

MMR and Varicella Vaccine in Premature Infants

Rubella | Mumps | Chickenpox | Rubeola

United States
GlaxoSmithKline

Completed

Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™

Measles | Rubella | Mumps | Varicella

Germany, Italy, France
Merck Sharp & Dohme LLC

Completed

Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027)

Measles | Rubella | Mumps | Varicella
GlaxoSmithKline

Completed

Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM

Measles | Rubella | Mumps | Varicella

India
GlaxoSmithKline

Completed

Immunogenicity & Safety Study of GSK Biologicals' Combined Measles-mumps-rubella-varicella Vaccine 208136

Measles | Rubella | Mumps | Varicella

Korea, Republic of

3

Subscribe